Impacts of medications for obesity on global health and the environment

A new generation of medications for obesity could transform the global food system. While research has explored their health impacts, their implications for global food demand and land use remain unquantified. We apply a global food system model to project the impact of glucagon-like peptide-1 receptor agonist (GLP-1) uptake to 2050 among people with obesity under two scenarios: reduced calorie intake while maintaining dietary composition, and reduced calorie intake combined with shifts towards the EAT–Lancet diet. Compared with the Reference scenario, GLP-1-mediated calorie reduction alone results in up to 6.6 million avoided deaths globally in 2050 and 32 Mha more natural land area, reflecting reductions in cropland, pasture and managed forest. Combining GLP-1 use with EAT–Lancet dietary shifts increases these estimates to 7.7 million avoided deaths and 46 Mha more natural land. Lower food prices increase food consumption among untreated populations, including unhealthy foods, partially offsetting these gains.

Authors

Institutions

Publication Details

Journal
Nature Communications
Published
2026-11-19
DOI
https://doi.org/10.1038/s41467-026-79412-w
Primary Topic
Agriculture Sustainability and Environmental Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impacts of medications for obesity on global health and the environment

Lindsay M. Jaacks, Roslyn Henry, Kaia Waxenberg
4 links
Nature Communications
Agriculture Sustainability and Environmental Impact
article

Impacts of medications for obesity on global health and the environment

Lindsay M. Jaacks, Roslyn Henry, Kaia Waxenberg
article en

Abstract

A new generation of medications for obesity could transform the global food system. While research has explored their health impacts, their implications for global food demand and land use remain unquantified. We apply a global food system model to project the impact of glucagon-like peptide-1 receptor agonist (GLP-1) uptake to 2050 among people with obesity under two scenarios: reduced calorie intake while maintaining dietary composition, and reduced calorie intake combined with shifts towards the EAT–Lancet diet. Compared with the Reference scenario, GLP-1-mediated calorie reduction alone results in up to 6.6 million avoided deaths globally in 2050 and 32 Mha more natural land area, reflecting reductions in cropland, pasture and managed forest. Combining GLP-1 use with EAT–Lancet dietary shifts increases these estimates to 7.7 million avoided deaths and 46 Mha more natural land. Lower food prices increase food consumption among untreated populations, including unhealthy foods, partially offsetting these gains.

Nature CommunicationsVol. 17(1)
University of Aberdeen (GB), Scotland's Rural College (GB), University of Edinburgh (GB)
Good health and well-being, Zero hunger, Responsible consumption and production
Agriculture Sustainability and Environmental Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon